Tocilizumab can be administered intravenously or subcutaneously. The route of administration may influence the pharmacokinetics and, subsequently, the histological outcomes. Intravenous administration allows for rapid delivery to the target tissues, which might be crucial in acute settings such as severe COVID-19. Subcutaneous administration is more convenient for chronic conditions like rheumatoid arthritis.
